Search Medical Condition
Please enter condition
Please choose location from dropdown

Human Papilloma Virus (HPV) Clinical Trials

A listing of Human Papilloma Virus (HPV) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (31) clinical trials

The purpose of this study is to evaluate the risk of cervical disease over a period of 3 years and to explore the experimental test as a cervical screening assay. The test results will be compared to the current standards of testing for HPV and diagnosing cervical disease.

Phase N/A

The Pap test (or Pap smear) looks for cancers and pre-cancers in the cervix (the lower part of the uterus that opens into the vagina). Pre-cancers are cell changes that might become cancer if they are not detected sooner or treated right away.

Phase N/A

Currently we have the following studies: Birth Control/ Contraceptive Vaginal Atrophy Pain During Intercourse Dysplasia Endometriosis Pap Smear Mammogram Bone Density Osteoporosis Nocturia Uterine Fibroids Uterine Bleeding Post Menopausal Studies HPV STD Hot Flashes

Phase N/A

The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)

In general, patients with Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma (HPVOPC) are curable, young and will live for prolonged periods. They are at high risk for long-term toxicity and mortality from therapy. While the long-term consequences of chemotherapy and surgery for head and neck cancer are relatively constrained, ...

Phase N/A

TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck

This is a single arm Phase II study of adjuvant radiation for locally-advanced p16+ oropharyngeal squamous cell carcinoma. Patients with pT0-T3, N0-N2b, M0 disease (per AJCC 7th ed) with <5 positive lymph nodes, will be eligible. Patients will have undergone TORS primary site resection and ipsilateral neck dissection. Patients will ...

Phase

Multilevel Interventions to Enhance Provider Recommendations for HPV Vaccination

The broad, long-term objective is to substantially increase human papillomavirus (HPV) vaccination rates by deploying effective population-health interventions in clinical practices across the United States. As part of this effort, the investigators intend to evaluate two evidence-based interventions with innovative enhancements at six Mayo Clinic primary care practices (PCP) to ...

Phase N/A

Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts

Patient selection: Female patients referred or presenting with genital warts at each site will be eligible and evaluated against the inclusion and exclusion criteria. Women who are clinically or severely immune-compromised will not be included into the study, but both HIV negative and HIV infected women will be included. Seventy-five ...

Phase

The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise

Viral infections in the normal host are usually self-limited as the innate and acquired immune systems mount successful antiviral responses. However, in some instances, apparently immunocompetent persons manifest infections with viruses that would otherwise be observed only in severely immunocompromised hosts. For example, cases of herpes simplex virus (HSV) encephalitis, ...

Phase N/A

Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)

Patients diagnosed with AIN 2/3 will be enrolled sequentially in treatment cohorts receiving different doses of Artesunate suppositories administered trans-anally. Doses of escalation will be 200 mg, 400 mg, and 600 mg. Treatment cohorts will consist of 2 or 3 cycles at each dose level. Suppositories will be administered daily ...

Phase

M7824 in Subjects With HPV Associated Malignancies

Background Metastatic or refractory/recurrent HPV associated malignancies (cervical, anal, oropharyngeal cancers etc.) are often incurable and poorly palliated by standard therapies. TGF R1 pathway signaling and overexpression are significantly associated with HPV+ cancers. PD-1 inhibitors have produced a 12-20% response rate for these diseases M7824 is a novel bifunctional fusion ...

Phase